1800 620 420
Close menu

The Trials Enabling Program (TEP)

In an Australian first, we’ve established the Trials Enabling Program (TEP) that will help people with blood cancer access promising new drugs through international clinical trials.

In 2015, the Leukaemia Foundation set out to address the lack of international clinical trial presence in Australia. We partnered with the nation’s leading blood cancer clinical trial group – the Australasian Leukaemia & Lymphoma Group (ALLG) – to establish TEP.

TEP is a mechanism that improves access of patients in Australia to the latest ground-breaking research and new therapies by bringing international clinical trials to Australia. TEP will deliver new therapeutic drugs to patients years ahead of the expected availability on the Australian market.

This innovative program is the first time an Australian charity has established a grant partnership to help patients access international blood cancer trials.

Trials Enabling Program: FAQs

Trials Enabling Program FAQs
Illustration of various treatments, pills, medicines

Clinical trial for Advanced Stage Hodgkin Lymphoma

Professor Mark Hertzberg

Clinical trial for high tumour burden follicular lymphoma

Judith Trotman

Clinical trial for newly diagnosed AML or MDS with IDH1 or IDH2 mutation

Assoc. Prof. Paula Marlton

Clinical trial for newly diagnosed AML or MDS with FLT3 mutation

Andrew Wei standing in a laboratory